Metallo-β-lactamases (MBLs) production in Gram negative bacilli is a major cause of concern among hospital associated urinary tract infection and is being increasingly reported worldwide. The bacteria having MBL has the potential to spread rapidly within the hospital environment and also across continents posing both therapeutic and control management problem. In recent years, MBL genes have spread from P.aeruginosa to members of the Enterobacteriaceae. So the present study was carried out with the aim to know the prevalence of MBLs in Gram negative bacteria from uropathogens and the antimicrobial resistant pattern of MBL. Total of 144 Gram negative bacteria were randomly selected. This isolates were tested for carbapenem resistance and MBL production by phenotypic method. Of 144 Gram negative bacilli isolated from urine, Carbapenem resistance was observed in 20(13.89%). Of these 12(8.33%) were from Enterobacteriaceae and 8(38.09%) from P.aeruginosa. A total of 7(4.86%) isolates were metallo-β-lactamases producer in Gram negative bacilli, 6(4.17%) were from P.aeruginosa and 1(0.69%) from Enterobacteriaceae. None of the isolates of E.coli, Proteus sps and Citrobacter sps were metallo-β-lactamases producer.
Oncological treatment is frequently followed by malfunction of cardiovascular system. Because of the high risk of developing cardiotoxicity after anticancer therapy, there is need for effective prevention.
Metallo-β-lactamases (MBLs) production in Gram negative bacilli is a major cause of concern among hospital associated urinary tract infection and is being increasingly reported worldwide.
An adverse cutaneous reaction to drugs is becoming a frequent phenomena affecting 2 - 3 % of the hospitalized patients with an approximate level of 1 in 1,000 total patients.
